A Lipid Gate for the Peripheral Control of Pain

Cells in injured and inflamed tissues produce a number of proalgesic lipid-derived mediators, which excite nociceptive neurons by activating selective G-protein-coupled receptors or ligand-gated ion channels. Recent work has shown that these proalgesic factors are counteracted by a distinct group of lipid molecules that lower nociceptor excitability and attenuate nociception in peripheral tissues. Analgesic lipid mediators include endogenous agonists of cannabinoid receptors (endocannabinoids), lipid-amide agonists of peroxisome proliferator-activated receptor-α, and products of oxidative metabolism of polyunsaturated fatty acids via cytochrome P450 and other enzyme pathways. Evidence indicates that these lipid messengers are produced and act at different stages of inflammation and the response to tissue injury, and may be part of a peripheral gating mechanism that regulates the access of nociceptive information to the spinal cord and the brain. Growing knowledge about this peripheral control system may be used to discover safer medicines for pain.

[1]  K. Mackie,et al.  Chronic Cannabinoid Receptor 2 Activation Reverses Paclitaxel Neuropathy Without Tolerance or Cannabinoid Receptor 1–Dependent Withdrawal , 2015, Biological Psychiatry.

[2]  K. Mackie,et al.  CB2 Cannabinoid Receptors as a Therapeutic Target—What Does the Future Hold? , 2014, Molecular Pharmacology.

[3]  T. Uyama,et al.  New players in the fatty acyl ethanolamide metabolism. , 2014, Pharmacological research.

[4]  Jun Yang,et al.  An omega‐3 epoxide of docosahexaenoic acid lowers blood pressure in angiotensin II‐dependent hypertension (832.5) , 2014, Journal of cardiovascular pharmacology.

[5]  Nghi Nguyen,et al.  Identification of Small Molecules That Selectively Inhibit Diacylglycerol Lipase–α Activity , 2014, Journal of biomolecular screening.

[6]  D. Piomelli,et al.  Peripheral gating of pain signals by endogenous lipid mediators , 2014, Nature Neuroscience.

[7]  B. Hammock,et al.  Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer. , 2014, Progress in lipid research.

[8]  S. Hwang,et al.  Epoxy Fatty Acids and Inhibition of the Soluble Epoxide Hydrolase Selectively Modulate GABA Mediated Neurotransmission to Delay Onset of Seizures , 2013, PloS one.

[9]  D. Simone,et al.  Increased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer pain , 2013, Neurobiology of Disease.

[10]  Sachin Patel,et al.  Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation , 2013, Nature Neuroscience.

[11]  Hau D. Le,et al.  Epoxyeicosanoids promote organ and tissue regeneration , 2013, Proceedings of the National Academy of Sciences.

[12]  B. Hammock,et al.  Use of a soluble epoxide hydrolase inhibitor as an adjunctive analgesic in a horse with laminitis. , 2013, Veterinary anaesthesia and analgesia.

[13]  V. Brázda,et al.  Bilateral Changes of Cannabinoid Receptor Type 2 Protein and mRNA in the Dorsal Root Ganglia of a Rat Neuropathic Pain Model , 2013, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[14]  C. Laezza,et al.  The endocannabinoid signaling system in cancer. , 2013, Trends in pharmacological sciences.

[15]  T. Uyama,et al.  Metabolism of endocannabinoids and related N‐acylethanolamines: Canonical and alternative pathways , 2013, The FEBS journal.

[16]  S. Hwang,et al.  Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis , 2013, Proceedings of the National Academy of Sciences.

[17]  R. Bertorelli,et al.  Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models , 2013, PAIN®.

[18]  B. Hammock,et al.  Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. , 2013, Annual review of pharmacology and toxicology.

[19]  H. Bradshaw,et al.  Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. , 2013, Pharmacological research.

[20]  P. Gervois,et al.  PPARα as a therapeutic target in inflammation-associated diseases , 2012, Expert opinion on therapeutic targets.

[21]  D. Piomelli,et al.  Peroxisome Proliferator-Activated Receptor α Mediates Acute Effects of Palmitoylethanolamide on Sensory Neurons , 2012, The Journal of Neuroscience.

[22]  Masahiko Watanabe,et al.  Behavioral / Systems / Cognitive Activation of Type 5 Metabotropic Glutamate Receptors and Diacylglycerol Lipase-Initiates 2-Arachidonoylglycerol Formation and Endocannabinoid-Mediated Analgesia , 2012 .

[23]  F. Haj,et al.  Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabetes , 2012, Proceedings of the National Academy of Sciences.

[24]  R. Bertorelli,et al.  Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions. , 2012, Pharmacological research.

[25]  B. Hammock,et al.  Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications. , 2012, Journal of medicinal chemistry.

[26]  O. Valverde,et al.  Alteration of neuropathic and visceral pain in female C57BL/6J mice lacking the PPAR-α gene , 2012, Psychopharmacology.

[27]  A. Lichtman,et al.  Discovery of Prostamide F2α and Its Role in Inflammatory Pain and Dorsal Horn Nociceptive Neuron Hyperexcitability , 2012, PloS one.

[28]  A. Cavalli,et al.  A catalytically silent FAAH-1 variant drives anandamide transport in neurons , 2011, Nature Neuroscience.

[29]  B. Hammock,et al.  Soluble epoxide hydrolase inhibition, epoxygenated fatty acids and nociception. , 2011, Prostaglandins & other lipid mediators.

[30]  이관호,et al.  Soluble epoxide hydrolase 억제제의 선별방법 , 2011 .

[31]  D. Piomelli,et al.  The ABC membrane transporter ABCG2 prevents access of FAAH inhibitor URB937 to the central nervous system. , 2011, Pharmacological research.

[32]  A. Hohmann,et al.  The endocannabinoid system and cancer: therapeutic implication , 2011, British journal of pharmacology.

[33]  D. Piomelli,et al.  Endocannabinoid signal in the gut controls dietary fat intake , 2011, Proceedings of the National Academy of Sciences.

[34]  P. Sassone-Corsi,et al.  Proinflammatory Stimuli Control N-Acylphosphatidylethanolamine-Specific Phospholipase D Expression in Macrophages , 2011, Molecular Pharmacology.

[35]  B. Hammock,et al.  Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMP , 2011, Proceedings of the National Academy of Sciences.

[36]  B. Hammock,et al.  Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids[S] , 2010, Journal of Lipid Research.

[37]  A. Hohmann,et al.  Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism , 2010, Nature Neuroscience.

[38]  A. Hohmann,et al.  Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms. , 2010, Pharmacological research.

[39]  D. Kendall,et al.  Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. , 2010, Immunobiology.

[40]  Agnes L. Bodor,et al.  The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors , 2010, Nature Neuroscience.

[41]  S. Cuzzocrea,et al.  Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation , 2009, Proceedings of the National Academy of Sciences.

[42]  A. Hohmann,et al.  The endocannabinoid system and pain. , 2009, CNS & neurological disorders drug targets.

[43]  D. Nomura,et al.  Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. , 2009, Chemistry & biology.

[44]  A. Akopian,et al.  Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. , 2009, Trends in pharmacological sciences.

[45]  D. Simone,et al.  A Decrease in Anandamide Signaling Contributes to the Maintenance of Cutaneous Mechanical Hyperalgesia in a Model of Bone Cancer Pain , 2008, The Journal of Neuroscience.

[46]  Charles N. Serhan,et al.  Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators , 2008, Nature Reviews Immunology.

[47]  A. Reeve,et al.  Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis , 2008, Arthritis research & therapy.

[48]  A. Hohmann,et al.  A physiological role for endocannabinoid‐derived products of cyclooxygenase‐2‐mediated oxidative metabolism , 2008, British journal of pharmacology.

[49]  A. Beitz,et al.  Chemical Interactions between Fibrosarcoma Cancer Cells and Sensory Neurons Contribute to Cancer Pain , 2007, The Journal of Neuroscience.

[50]  K. Mackie,et al.  Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors , 2007, Nature Neuroscience.

[51]  B. Hammock,et al.  Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors , 2006, Proceedings of the National Academy of Sciences.

[52]  A. Hohmann,et al.  Rapid Broad-Spectrum Analgesia through Activation of Peroxisome Proliferator-Activated Receptor-α , 2006, Journal of Pharmacology and Experimental Therapeutics.

[53]  K. Mackie,et al.  Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain , 2006, Pain.

[54]  B. Hammock,et al.  Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors , 2006, Proceedings of the National Academy of Sciences.

[55]  P. McIntyre,et al.  Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons , 2005, Neuroscience.

[56]  W. Wahli,et al.  PPARs in diseases: control mechanisms of inflammation. , 2005, Current medicinal chemistry.

[57]  Roberto Russo,et al.  The search for the palmitoylethanolamide receptor. , 2005, Life sciences.

[58]  B. Hammock,et al.  Soluble epoxide hydrolase is a therapeutic target for acute inflammation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[59]  D. R. Sagar,et al.  Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats , 2005, The European journal of neuroscience.

[60]  J. Crystal,et al.  An endocannabinoid mechanism for stress-induced analgesia , 2005, Nature.

[61]  C. M. Baker,et al.  Tumor-induced mechanical hyperalgesia involves CGRP receptors and altered innervation and vascularization of DsRed2 fluorescent hindpaw tumors , 2005, Pain.

[62]  A. Hohmann,et al.  Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. , 2004, Journal of neurophysiology.

[63]  A. Akopian,et al.  Modulation of trigeminal sensory neuron activity by the dual cannabinoid–vanilloid agonists anandamide, N‐arachidonoyl‐dopamine and arachidonyl‐2‐chloroethylamide , 2004, British journal of pharmacology.

[64]  B. Taylor,et al.  Peroxisome Proliferator-Activated Receptor Agonists Inhibit Inflammatory Edema and Hyperalgesia , 2002, Inflammation.

[65]  S. Gaetani,et al.  Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α , 2003, Nature.

[66]  A. Hohmann,et al.  Selective activation of cannabinoid CB2 receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation , 2003, Neuroscience.

[67]  A. Hohmann,et al.  A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation , 2003, Neuroscience.

[68]  S. Gaetani,et al.  Modulation of anxiety through blockade of anandamide hydrolysis , 2003, Nature Medicine.

[69]  T. Freund,et al.  Brain monoglyceride lipase participating in endocannabinoid inactivation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[70]  Martin Koltzenburg,et al.  Molecular mechanisms of cancer pain , 2002, Nature Reviews Cancer.

[71]  A. Beitz,et al.  Functional Interactions between Tumor and Peripheral Nerve: Morphology, Algogen Identification, and Behavioral Characterization of a New Murine Model of Cancer Pain , 2001, The Journal of Neuroscience.

[72]  A. Beitz,et al.  Functional interactions between tumor and peripheral nerve in a model of cancer pain in the mouse. , 2001, Pain medicine.

[73]  P. Mantyh,et al.  Neurochemical and Cellular Reorganization of the Spinal Cord in a Murine Model of Bone Cancer Pain , 1999, The Journal of Neuroscience.

[74]  M. Herkenham,et al.  Cannabinoid receptors undergo axonal flow in sensory nerves , 1999, Neuroscience.

[75]  S. Mercadante.  Pain treatment and outcomes for patients with advanced cancer who receive follow‐up care at home , 1999, Cancer.

[76]  D. Piomelli,et al.  Control of pain initiation by endogenous cannabinoids , 1998, Nature.

[77]  J. D. Richardson,et al.  Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors , 1998, Pain.

[78]  D. Piomelli,et al.  A second endogenous cannabinoid that modulates long-term potentiation , 1997, Nature.

[79]  W. Wahli,et al.  The PPARα–leukotriene B4 pathway to inflammation control , 1996, Nature.

[80]  W. Wahli,et al.  The PPARalpha-leukotriene B4 pathway to inflammation control. , 1996, Nature.

[81]  Duchen,et al.  Differential expression of membrane currents in dissociated mouse primary sensory neurons , 1990, Neuroscience.

[82]  M. Herkenham,et al.  Characterization and localization of cannabinoid receptors in brain: an in vitro technique using slide-mounted tissue sections. , 1991, NIDA research monograph.

[83]  A. Hiura,et al.  Quantitative estimation of the effects of capsaicin on the mouse primary sensory neurons , 1987, Neuroscience Letters.

[84]  S. Ferreira.  Prostaglandins, aspirin-like drugs and analgesia. , 1972, Nature: New biology.

[85]  M. Sugawara.  The National Research Centre for Disaster Prevention , 1972, Nature.